Table of Content

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Digitization in the Healthcare Sector
3.3. Next-Generation Healthcare Solutions
3.4. Key Concepts Associated with Digital Health Solutions
3.4.1. Cognitive Behavioral Therapy (CBT)
3.4.2. Internet of Things (IoT)
3.4.3. Big Data
3.4.4. Artificial Intelligence (AI)
3.4.5. Gamification
3.5. Overview of Digital Therapeutics
3.5.1. Key Strategic Initiatives
3.5.1.1. Digital Therapeutics Alliance (DTA)
3.5.1.2. Personal Connected Health (PCH) Alliance
3.5.1.3. Programs Initiated by The Centers for Disease Control and Prevention (CDC)
3.5.1.4. Health Insurance Portability and Accountability Act (HIPAA)
3.5.1.5. National Health Service (NHS) Guidelines
3.5.1.6. United States Food and Drug Administration (USFDA) Regulations for Digital Therapeutics
3.5.2. Typical Development and Commercialization Path for Digital Therapeutics
3.5.2.1. Discovery and Preclinical Phase
3.5.2.2. Clinical Trials and Validation
3.5.2.3. Negotiation Involving Insurance Providers / Payers
3.5.2.4. Distribution and Marketing
3.6 Concluding Remarks

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Therapeutics: Overall Market Landscape
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Solution
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Purpose of Solution
4.2.5. Analysis by Target Indication
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Target Population
4.3. Digital Therapeutics: Additional Information
4.3.1. Analysis by Requirement of Prescription
4.3.2. Analysis by Duration of Course
4.3.3. Analysis by Cost of Solution
4.4. Digital Therapeutics: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Type of Business Model
4.4.4. Analysis by Location of Headquarters
4.5. Leading Developers: Analysis by Number of Digital Therapeutic Solutions
4.6. Leading Developers: Analysis by Portfolio Strength, Target Indication, and Company Size (4D Bubble Representation)
4.7. Analysis by Therapeutic Area and Company Size (Tree Map Representation)
4.8. Analysis of Regional Activity (World Map Representation)

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions / Key Parameter
5.3. Methodology
5.4. Key Therapeutic Areas
5.4.1. Product Competitive Analysis: Digital Therapeutics Targeting Cardiovascular Disorders
5.4.2. Product Competitive Analysis: Digital Therapeutics Targeting Mental Health Problems
5.4.3. Product Competitive Analysis: Digital Therapeutics Targeting Metabolic Disorders
5.4.4. Product Competitive Analysis: Digital Therapeutics Targeting Neurological Disorders
5.4.5. Product Competitive Analysis: Digital Therapeutics Targeting Substance Use Disorders
5.4.6. Product Competitive Analysis: Digital Therapeutics Targeting Other Therapeutic Areas

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Akili Interactive
6.2.1. Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Big Health
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. dreem
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Kaia Health
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. MindMaze
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Omada Health
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Pear Therapeutics
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3. Recent Developments and Future Outlook
6.9. Vida Health
6.9.1. Company Overview
6.9.2. Product Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Voluntis
6.10.1. Company Overview
6.10.2. Product Portfolio
6.10.3. Recent Developments and Future Outlook
6.11. WellDoc
6.11.1. Company Overview
6.11.2. Product Portfolio
6.11.3. Recent Developments and Future Outlook
6.12. Wellthy Therapeutics
6.12.1. Company Overview
6.12.2. Product Portfolio
6.12.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Digital Therapeutics: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Status
7.3.3. Analysis by Trial Registration Year and Trial Status
7.3.4. Analysis by Trial Phase
7.3.5. Analysis by Type of Study
7.3.6. Analysis by Study Design
7.3.7. Analysis by Study Age
7.3.8. Analysis by Gender of Patients
7.3.9. Analysis of Patients Enrolled by Trial Registration Year
7.3.10. Analysis by Type of Sponsor
7.3.11. Analysis by Focus Area
7.3.12. Analysis by Geography
7.3.13. Analysis by Trial Registration Year, Recruitment Status and Geography
7.3.14. Analysis of Patients Enrolled by Geography
7.4. Clinical End-Points Analysis

8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Type of Funding Models
8.3. Digital therapeutics: List of Funding and Investments
8.3.1. Analysis of Number of Funding Instances by Year of Establishment and Type of Funding
8.3.2. Analysis of Funding Instances by Year
8.3.3. Analysis of Amount Invested by Year
8.3.4. Analysis by Type of Funding
8.3.5. Analysis of Instances and Amount Invested by Type of Therapy
8.3.6. Analysis by Therapeutic Area
8.3.7. Analysis by Geography
8.3.8. Most Active Players: Analysis by Number of Instances
8.3.9. Most Active Players: Analysis by Amount Raised
8.3.10. Most Active Investors: Analysis by Number of Instances
8.4. Concluding Remarks

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Digital Therapeutics: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.2.1. Analysis by Year of Partnership and Type of Partnership
9.3.2.2. Analysis by Type of Partnership and Company Size
9.3.3. Analysis by Type of Partner
9.3.3.1. Analysis by Year of Partnership and Type of Partner
9.3.3.2. Analysis by Type of Partnership and Type of Partner
9.3.3.3. Analysis by Type of Partner and Company Size
9.3.4. Analysis by Type of Therapy
9.3.4.1. Analysis by Type of Partnership and Type of Therapy
9.3.4.2. Analysis by Type of Partner and Type of Therapy
9.3.5. Analysis by Therapeutic Area
9.3.5.1. Analysis by Year of Partnership and Therapeutic Area
9.3.5.2. Analysis by Type of Partner and Therapeutic Area
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Analysis by Geography
9.3.8. Intercontinental and Intracontinental Agreements
10. GO-TO-MARKET STRATEGY
10.1. Chapter Overview
10.2. Marketing Strategies Adopted by Digital Therapeutic Developers
10.2.1. Participation in Global Events
10.2.2. Marketing on Social Media Platforms
10.2.3. Marketing on Online / Print Media Platforms
10.2.4. Undertaking Various Promotional Activities through Official Websites
10.2.5. Adoption of Different Business Models
10.2.5.1. B2C Business Model
10.2.5.2. B2B Business Model
10.2.5.2. B2B2C Business Model
10.2.6. Undertaking Various Promotional Activities through Product Add-ons
10.3. Concluding Remarks
11. BOWMAN CLOCK PRICING STRATEGY ANALYSIS
11.1. Chapter Overview
11.2. Bowman Strategy Clock
11.2.1. Two Dimensions of Bowman Strategy Clock
11.2.2. Eight Positions on Bowman Strategic Clock
11.3. Roots Analysis Framework
11.3.1. Methodology
11.3.2. Theoretical Framework and Price Evaluation Hypothesis
11.3.3. Results and Interpretation
11.3.3.1. Product Price Evaluation Matrix: Based on Status of Development
11.3.3.2. Product Price Evaluation Matrix: Based on Type of Solution
11.3.3.3. Product Price Evaluation Matrix: Based on Purpose of Solution
11.3.3.4. Product Price Evaluation Matrix: Based on Type of Therapy
11.3.3.5. Product Price Evaluation Matrix: Based on Therapeutic Area
11.3.3.6. Product Price Evaluation Matrix: Based on Prescription Requirement
11.3.3.7. Product Price Evaluation Matrix: Based on Duration of Course
11.3.3.8. Product Price Evaluation Matrix: Based on Distribution Channel
11.4. Concluding Remarks

12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Digital Therapeutics Market, 2022-2035
12.4. Digital Therapeutics Market: Analysis by Type of Solution, 2022-2035
12.4.1. Digital Therapeutics Market for Standalone Software Applications, 2022-2035
12.4.2. Digital Therapeutics Market for Combination Offerings focused on Software Application, Device and Personal Coach, 2022-2035
12.4.3. Digital Therapeutics Market for Combination Offerings focused on Software Application and Personal Coach, 2022-2035
12.4.4. Digital Therapeutics Market for Combination Offerings focused on Software Application and AI Support, 2022-2035
12.4.5. Digital Therapeutics Market for Combination Offerings focused on Software Application and Device), 2022-2035
12.4.6. Digital Therapeutics Market for Combination Offerings focused on Software Application, Device and AI Support), 2022-2035
12.4.7. Digital Therapeutics Market for Other Types of Solutions, 2022-2035
12.5. Digital Therapeutics Market: Analysis by Purpose of Solution, 2022-2035
12.5.1. Digital Therapeutics Market for Medication Replacement Solutions, 2022-2035
12.5.2. Digital Therapeutics Market for Medication Augmentation Solutions, 2022-2035
12.6. Digital Therapeutics Market: Analysis by Type of Therapy, 2022-2035
12.6.1. Digital Therapeutics Market for Curative Therapy, 2022-2035
12.6.2. Digital Therapeutics Market for Preventive Therapy, 2022-2035
12.7. Digital Therapeutics Market: Analysis by Business Model, 2022-2035
12.7.1. Digital Therapeutics Market for B2C Model, 2022-2035
12.7.2. Digital Therapeutics Market for B2B Model, 2022-2035
12.8. Digital Therapeutics Market: Analysis by Therapeutic Area, 2022-2035
12.8.1. Digital Therapeutics Market for Cardiovascular Disorders, 2022-2035
12.8.2. Digital Therapeutics Market for Chronic Pain, 2022-2035
12.8.3. Digital Therapeutics Market for Mental Health Problems, 2022-2035
12.8.4. Digital Therapeutics Market for Metabolic Disorders, 2022-2035
12.8.5. Digital Therapeutics Market for Neurological Disorders, 2022-2035
12.8.6. Digital Therapeutics Market for Respiratory Disorders, 2022-2035
12.8.7. Digital Therapeutics Market for Sleep Disorders, 2022-2035
12.8.8. Digital Therapeutics Market for Substance Use Disorders, 2022-2035
12.8.9. Digital Therapeutics Market for Other Disorders, 2022-2035
12.9. Digital Therapeutics Market: Analysis by Geography, 2022-2035
12.9.1. Digital Therapeutics Market in North America, 2022-2035
12.9.2. Digital Therapeutics Market in Europe, 2022-2035
12.9.3. Digital Therapeutics Market in Asia, 2022-2035
12.9.4. Digital Therapeutics Market in MENA, 2022-2035
12.9.5. Digital Therapeutics Market in Latin America, 2022-2035
12.9.6. Digital Therapeutics Market in Rest of the World, 2022-2035
12.10. Concluding Remarks

13. WOMEN DIGITAL HEALTH: AN EMERGING NEW CONCEPT
13.1. Introduction: Women Digital Health
13.2. Chapter Overview
13.3. Women’s Digital Health: Product Pipeline
13.3.1. Analysis by Type of Solution
13.3.2. Analysis by Status of Development
13.3.3. Analysis by Product Ratings
13.3.4. Analysis by Application Area
13.3.5. Analysis of Products by Different Stages of Pregnancy
13.3.6. Analysis by Purpose of Solution
13.3.7. Analysis by Type of End-Users
13.3.8. Analysis by Type of Solution and Application Area
13.4. Women’s Digital Health: Developer’s Landscape
13.4.1. Analysis by Year of Establishment
13.4.2. Analysis by Company Size
13.4.3. Analysis by Location of Headquarters (Region-wise)
13.4.4. Analysis by Company Size and Region
13.4.5. Analysis by Location of Headquarters (Country-Wise)
13.4.6. Leading Players: Analysis by Number of Solutions
13.4.7. Regional Landscape: Analysis by Type of Solution

14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Comparison of SWOT Factors
14.2.1. Strengths
14.2.2. Weaknesses
14.2.3. Opportunities
14.2.4. Threats
14.2.5. Conclusion

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Ampersand Health
15.2.1. Company Snapshot
15.2.2. Interview Transcript
15.3. Canary Health
15.3.1. Company Snapshot
15.3.2. Interview Transcript
15.4. Dnurse Technology
15.4.1. Company Snapshot
15.4.2. Interview Transcript

15.5. Embr Labs
15.5.1. Company Snapshot
15.5.2. Interview Transcript
15.6. Exosystems
15.6.1. Company Snapshot
15.6.2. Interview Transcript
15.7. Floreo
15.7.1. Company Snapshot
15.7.2. Interview Transcript
15.8. GAIA
15.8.1. Company Snapshot
15.8.2. Interview Transcript
15.9. Healios
15.9.1. Company Snapshot
15.9.2. Interview Transcript
15.10. JOGGO Health
15.10.1. Company Snapshot
15.10.2. Interview Transcript
15.11. metaMe Health
15.11.1. Company Snapshot
15.11.2. Interview Transcript
15.12. SelfBack
15.12.1. Company Snapshot
15.12.2. Interview Transcript
15.13. Somatix
15.13.1. Company Snapshot
15.13.2. Interview Transcript
15.14. Tilak Healthcare
15.14.1. Company Snapshot
15.14.2. Interview Transcript
15.15. Turnaround Health
15.15.1. Company Snapshot
15.15.2. Interview Transcript
15.16. Vida Health
15.16.1. Company Snapshot
15.16.2. Interview Transcript
15.17. Voluntis
15.17.1. Company Snapshot
15.17.2. Interview Transcript
15.18. Wellthy Therapeutics
15.18.1. Company Snapshot
15.18.2. Interview Transcript
15.19. Undisclosed
15.19.1. Interview Transcript: Founder and Chief Executive Officer

16. CONCLUDING REMARKS

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS